New Risk • Jul 21
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.1% average weekly change). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Announcement • Jul 15
Bliss GVS Pharma Limited Approves Final Dividend for the Financial Year Ended March 31, 2026 Bliss GVS Pharma Limited at its 41st annual general meeting held on July 15, 2026, approved the payment of a final dividend of 100% (INR 1.00 per equity share of face value of INR 1 each) for the financial year ended March 31, 2026. Board Change • Jul 03
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Independent Women Director Shilpa Bhatia is the most experienced director on the board, commencing their role in 2020. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Upcoming Dividend • Jul 01
Upcoming dividend of ₹1.00 per share Eligible shareholders must have bought the stock before 08 July 2026. Payment date: 14 August 2026. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.7%). Reported Earnings • Jun 24
Full year 2026 earnings released: EPS: ₹12.23 (vs ₹8.02 in FY 2025) Full year 2026 results: EPS: ₹12.23 (up from ₹8.02 in FY 2025). Revenue: ₹10.0b (up 24% from FY 2025). Net income: ₹1.29b (up 53% from FY 2025). Profit margin: 13% (up from 10% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 79% per year, which means it is tracking significantly ahead of earnings growth. New Risk • May 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • May 26
Investor sentiment improves as stock rises 35% After last week's 35% share price gain to ₹381, the stock trades at a trailing P/E ratio of 37x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 433% over the past three years. Announcement • May 13
Bliss GVS Pharma Limited, Annual General Meeting, Jul 15, 2026 Bliss GVS Pharma Limited, Annual General Meeting, Jul 15, 2026, at 11:00 Indian Standard Time. Announcement • May 05
Bliss GVS Pharma Limited to Report Q4, 2026 Results on May 12, 2026 Bliss GVS Pharma Limited announced that they will report Q4, 2026 results on May 12, 2026 Reported Earnings • Feb 13
Third quarter 2026 earnings released: EPS: ₹2.20 (vs ₹2.27 in 3Q 2025) Third quarter 2026 results: EPS: ₹2.20 (down from ₹2.27 in 3Q 2025). Revenue: ₹2.18b (up 3.7% from 3Q 2025). Net income: ₹232.7m (down 2.3% from 3Q 2025). Profit margin: 11% (in line with 3Q 2025). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Feb 12
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹218, the stock trades at a trailing P/E ratio of 21x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 182% over the past three years. Announcement • Feb 03
Bliss GVS Pharma Limited to Report Q3, 2026 Results on Feb 10, 2026 Bliss GVS Pharma Limited announced that they will report Q3, 2026 results at 12:15 PM, Indian Standard Time on Feb 10, 2026 Valuation Update With 7 Day Price Move • Jan 29
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹183, the stock trades at a trailing P/E ratio of 17.7x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 152% over the past three years. Valuation Update With 7 Day Price Move • Dec 12
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹144, the stock trades at a trailing P/E ratio of 13.9x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 102% over the past three years. New Risk • Dec 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.6% average weekly change). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Valuation Update With 7 Day Price Move • Nov 14
Investor sentiment improves as stock rises 26% After last week's 26% share price gain to ₹162, the stock trades at a trailing P/E ratio of 15.6x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 126% over the past three years. New Risk • Nov 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.2% average weekly change). Buy Or Sell Opportunity • Nov 07
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 28% to ₹128. The fair value is estimated to be ₹161, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.8% over the last 3 years. Earnings per share has grown by 20%. Announcement • Oct 29
Bliss GVS Pharma Limited to Report Q2, 2026 Results on Nov 06, 2025 Bliss GVS Pharma Limited announced that they will report Q2, 2026 results on Nov 06, 2025 Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹179, the stock trades at a trailing P/E ratio of 17.7x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 133% over the past three years. New Risk • Jul 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.8% average weekly change). Announcement • Jul 22
Bliss GVS Pharma Limited to Report Q1, 2026 Results on Jul 29, 2025 Bliss GVS Pharma Limited announced that they will report Q1, 2026 results on Jul 29, 2025 Upcoming Dividend • Jul 17
Upcoming dividend of ₹0.50 per share Eligible shareholders must have bought the stock before 24 July 2025. Payment date: 30 August 2025. Payout ratio is a comfortable 6.2% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.8%). Reported Earnings • Jul 14
Full year 2025 earnings released: EPS: ₹8.02 (vs ₹7.23 in FY 2024) Full year 2025 results: EPS: ₹8.02 (up from ₹7.23 in FY 2024). Revenue: ₹8.10b (up 5.1% from FY 2024). Net income: ₹843.0m (up 12% from FY 2024). Profit margin: 10% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth. Declared Dividend • May 14
Dividend of ₹0.50 announced Dividend of ₹0.50 is the same as last year. Ex-date: 24th July 2025 Payment date: 30th August 2025 Dividend yield will be 0.4%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (7% earnings payout ratio) and cash flows (18% cash payout ratio). The dividend has remained flat since 10 years ago. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 92% to shift the payout ratio to a potentially unsustainable range, which is more than the 3.2% EPS decline seen over the last 5 years. Announcement • May 13
Bliss GVS Pharma Limited, Annual General Meeting, Jul 31, 2025 Bliss GVS Pharma Limited, Annual General Meeting, Jul 31, 2025, at 11:30 Indian Standard Time. Reported Earnings • May 13
Full year 2025 earnings released: EPS: ₹8.02 (vs ₹7.23 in FY 2024) Full year 2025 results: EPS: ₹8.02 (up from ₹7.23 in FY 2024). Revenue: ₹8.46b (up 9.9% from FY 2024). Net income: ₹843.0m (up 12% from FY 2024). Profit margin: 10.0% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth. Announcement • May 12
Bliss GVS Pharma Limited Recommends Final Dividend for the Financial Year Ended March 31, 2025 Bliss GVS Pharma Limited announced that at its board meeting held on May 12, 2025, has recommended Final dividend of 50% or 0.50 paisa per equity share on face value of INR 1 each for the financial year ended March 31, 2025, subject To Approve the shareholders in the forthcoming 40th Annual General Meeting of the Company. Announcement • May 05
Bliss GVS Pharma Limited to Report Q4, 2025 Results on May 12, 2025 Bliss GVS Pharma Limited announced that they will report Q4, 2025 results on May 12, 2025 Recent Insider Transactions • Feb 24
Insider recently bought ₹13m worth of stock On the 19th of February, Shibroor Kamath bought around 100k shares on-market at roughly ₹129 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Valuation Update With 7 Day Price Move • Feb 12
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹138, the stock trades at a trailing P/E ratio of 24.4x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 56% over the past three years. Reported Earnings • Jan 29
Third quarter 2025 earnings released: EPS: ₹2.27 (vs ₹2.64 in 3Q 2024) Third quarter 2025 results: EPS: ₹2.27 (down from ₹2.64 in 3Q 2024). Revenue: ₹2.26b (up 12% from 3Q 2024). Net income: ₹238.0m (down 14% from 3Q 2024). Profit margin: 11% (down from 14% in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Announcement • Jan 21
Bliss GVS Pharma Limited to Report Q3, 2025 Results on Jan 28, 2025 Bliss GVS Pharma Limited announced that they will report Q3, 2025 results at 12:15 PM, Indian Standard Time on Jan 28, 2025 Valuation Update With 7 Day Price Move • Nov 27
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹143, the stock trades at a trailing P/E ratio of 23.7x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total returns to shareholders of 47% over the past three years. Reported Earnings • Oct 26
Second quarter 2025 earnings released: EPS: ₹2.31 (vs ₹4.06 in 2Q 2024) Second quarter 2025 results: EPS: ₹2.31 (down from ₹4.06 in 2Q 2024). Revenue: ₹2.23b (up 5.1% from 2Q 2024). Net income: ₹242.6m (down 43% from 2Q 2024). Profit margin: 11% (down from 20% in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Oct 25
Investor sentiment deteriorates as stock falls 22% After last week's 22% share price decline to ₹109, the stock trades at a trailing P/E ratio of 14x. Average trailing P/E is 38x in the Pharmaceuticals industry in India. Negligible returns to shareholders over past three years. Announcement • Oct 24
Bliss GVS Pharma Limited Appoints Nandkumar Kashinath Chodankar as Chairman of the Board Bliss GVS Pharma Limited at the Board Meeting held on October 24, 2024 announced following the completion of the second and final term of Mr. Subramanian Ramaswamy Vaidya as Independent Director and Former Chairman of the Board, the Company has appointed Mr. Nandkumar Kashinath Chodankar, currently serving as Non-Executive Independent Director, as the new Chairman of the Board, effective from October 24, 2024. Buy Or Sell Opportunity • Oct 21
Now 24% undervalued Over the last 90 days, the stock has risen 18% to ₹132. The fair value is estimated to be ₹173, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last 3 years. Earnings per share has grown by 28%. Announcement • Oct 20
Bliss GVS Pharma Limited to Report Q2, 2025 Results on Oct 24, 2024 Bliss GVS Pharma Limited announced that they will report Q2, 2025 results on Oct 24, 2024 Announcement • Aug 27
Bliss GVS Pharma Limited Announces Cessation of Subramanian Ramaswamy Vaidya as an Independent Director Bliss GVS Pharma Limited announced that Mr. Subramanian Ramaswamy Vaidya has completed his second and final term as an Independent Director. Consequently, he has ceased to be a director of the company since the close of business hours on August 27, 2024. Valuation Update With 7 Day Price Move • Aug 21
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹127, the stock trades at a trailing P/E ratio of 16.4x. Average trailing P/E is 37x in the Pharmaceuticals industry in India. Total returns to shareholders of 28% over the past three years. Announcement • Jul 25
Bliss GVS Pharma Limited Approves Final Dividend for the Financial Year Ended March 31, 2024 Bliss GVS Pharma Limited announced that at its AGM held on July 25, 2024, the shareholders approved final dividend of 50% that is INR 0.50 per equity share on face value of INR 1 each for the financial year ended March 31, 2024. Buy Or Sell Opportunity • Jul 25
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 2.8% to ₹119. The fair value is estimated to be ₹150, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last 3 years. Earnings per share has grown by 28%. Announcement • Jul 17
Bliss GVS Pharma Limited to Report Q1, 2025 Results on Jul 24, 2024 Bliss GVS Pharma Limited announced that they will report Q1, 2025 results on Jul 24, 2024 Upcoming Dividend • Jul 11
Upcoming dividend of ₹0.50 per share Eligible shareholders must have bought the stock before 18 July 2024. Payment date: 24 August 2024. Payout ratio is a comfortable 6.9% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.1%). Lower than average of industry peers (0.7%). Reported Earnings • Jul 08
Full year 2024 earnings released: EPS: ₹7.23 (vs ₹6.83 in FY 2023) Full year 2024 results: EPS: ₹7.23 (up from ₹6.83 in FY 2023). Revenue: ₹7.70b (up 2.5% from FY 2023). Net income: ₹754.5m (up 6.5% from FY 2023). Profit margin: 9.8% (in line with FY 2023). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Declared Dividend • May 09
Dividend of ₹0.50 announced Dividend of ₹0.50 is the same as last year. Ex-date: 18th July 2024 Payment date: 24th August 2024 Dividend yield will be 0.5%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (7% earnings payout ratio) and cash flows (4% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. The company's earnings per share (EPS) would need to decline by 92% to shift the payout ratio to a potentially unsustainable range, which is more than the 9.7% EPS decline seen over the last 5 years. New Risk • May 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 14% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.3% average weekly change). Buy Or Sell Opportunity • May 06
Now 23% undervalued after recent price drop Over the last 90 days, the stock has fallen 5.6% to ₹113. The fair value is estimated to be ₹147, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.5% over the last 3 years. Earnings per share has grown by 19%. Reported Earnings • May 04
Full year 2024 earnings released: EPS: ₹7.23 (vs ₹6.83 in FY 2023) Full year 2024 results: EPS: ₹7.23 (up from ₹6.83 in FY 2023). Revenue: ₹7.99b (up 6.3% from FY 2023). Net income: ₹754.5m (up 6.5% from FY 2023). Profit margin: 9.4% (in line with FY 2023). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Announcement • Apr 28
Bliss GVS Pharma Limited to Report Q4, 2024 Results on May 02, 2024 Bliss GVS Pharma Limited announced that they will report Q4, 2024 results on May 02, 2024 Valuation Update With 7 Day Price Move • Feb 19
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹132, the stock trades at a trailing P/E ratio of 15.7x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total loss to shareholders of 24% over the past three years. Board Change • Feb 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. MD & Director Gagan Sharma was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Jan 24
Third quarter 2024 earnings released: EPS: ₹2.64 (vs ₹2.68 in 3Q 2023) Third quarter 2024 results: EPS: ₹2.64 (down from ₹2.68 in 3Q 2023). Revenue: ₹2.06b (flat on 3Q 2023). Net income: ₹276.1m (down 1.2% from 3Q 2023). Profit margin: 13% (in line with 3Q 2023). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. New Risk • Jan 18
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.1% average weekly change). Earnings have declined by 14% per year over the past 5 years. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Announcement • Jan 17
Bliss GVS Pharma Limited to Report Q3, 2024 Results on Jan 23, 2024 Bliss GVS Pharma Limited announced that they will report Q3, 2024 results on Jan 23, 2024 New Risk • Nov 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 14% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.5% average weekly change). Reported Earnings • Nov 03
Second quarter 2024 earnings released: EPS: ₹4.06 (vs ₹1.33 in 2Q 2023) Second quarter 2024 results: EPS: ₹4.06 (up from ₹1.33 in 2Q 2023). Revenue: ₹2.24b (up 30% from 2Q 2023). Net income: ₹423.1m (up 205% from 2Q 2023). Profit margin: 19% (up from 8.0% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings. Valuation Update With 7 Day Price Move • Nov 02
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹96.57, the stock trades at a trailing P/E ratio of 16.9x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total loss to shareholders of 42% over the past three years. Announcement • Oct 26
Bliss GVS Pharma Limited to Report First Half, 2024 Results on Nov 01, 2023 Bliss GVS Pharma Limited announced that they will report first half, 2024 results on Nov 01, 2023 Announcement • Aug 03
Bliss Gvs Pharma Limited Announces Change in the Designation of Mr. Vishal Vijay Rao Bliss GVS Pharma Limited announced Change in the designation of Mr. Vishal Vijay Rao from the position of General Manager to Vice-President, Senior Management Personnel of the Company. Apart from such change, all the other terms and conditions of his appointment will remain intact & same which were duly approved by the shareholders of the Company in their 36th Annual General Meeting dated September 21, 2021. Reported Earnings • Aug 02
First quarter 2024 earnings released: EPS: ₹1.41 (vs ₹2.48 in 1Q 2023) First quarter 2024 results: EPS: ₹1.41 (down from ₹2.48 in 1Q 2023). Revenue: ₹1.65b (down 13% from 1Q 2023). Net income: ₹146.9m (down 43% from 1Q 2023). Profit margin: 8.9% (down from 14% in 1Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Announcement • Jul 25
Bliss GVS Pharma Limited to Report Q1, 2024 Results on Aug 01, 2023 Bliss GVS Pharma Limited announced that they will report Q1, 2024 results on Aug 01, 2023 Announcement • Jul 22
Bliss GVS Pharma Limited Declares Final Dividend for the Financial Year Ended March 31, 2023 Bliss GVS Pharma Limited at its AGM held on July 19, 2023, declared a final dividend of 50% i.e. INR 0.50 per equity share on the face value of INR 1.00 each for the Financial Year ended March 31, 2023. Valuation Update With 7 Day Price Move • Jul 14
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹90.61, the stock trades at a trailing P/E ratio of 13.3x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total loss to shareholders of 14% over the past three years. Upcoming Dividend • Jul 05
Upcoming dividend of ₹0.50 per share at 0.7% yield Eligible shareholders must have bought the stock before 12 July 2023. Payment date: 18 August 2023. Payout ratio is a comfortable 7.3% but the company is not cash flow positive. Trailing yield: 0.7%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (1.0%). Reported Earnings • May 13
Full year 2023 earnings released: EPS: ₹6.83 (vs ₹1.46 in FY 2022) Full year 2023 results: EPS: ₹6.83 (up from ₹1.46 in FY 2022). Revenue: ₹7.69b (up 2.9% from FY 2022). Net income: ₹708.6m (up 371% from FY 2022). Profit margin: 9.2% (up from 2.0% in FY 2022). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Announcement • May 13
Bliss GVS Pharma Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023 The board of directors of Bliss GVS Pharma Limited meeting held on May 11, 2023, recommended final dividend of 50% i.e. 0.50 paisa per equity share having face value of INR 1/- each for the financial year ended March 31, 2023, subject To Approve the shareholders in the forthcoming 38th Annual General Meeting of the Company. Announcement • May 12
Bliss GVS Pharma Limited, Annual General Meeting, Jun 19, 2023 Bliss GVS Pharma Limited, Annual General Meeting, Jun 19, 2023, at 11:00 Indian Standard Time. Agenda: To consider the dividend. Announcement • May 06
Bliss GVS Pharma Limited to Report Q4, 2023 Results on May 11, 2023 Bliss GVS Pharma Limited announced that they will report Q4, 2023 results on May 11, 2023 Recent Insider Transactions • Feb 21
Insider recently bought ₹23m worth of stock On the 16th of February, Shibroor Kamath bought around 300k shares on-market at roughly ₹77.24 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₹100m more in shares than they have sold in the last 12 months. Reported Earnings • Jan 25
Third quarter 2023 earnings released: EPS: ₹2.68 (vs ₹4.83 loss in 3Q 2022) Third quarter 2023 results: EPS: ₹2.68 (up from ₹4.83 loss in 3Q 2022). Revenue: ₹2.11b (down 2.3% from 3Q 2022). Net income: ₹279.4m (up ₹780.5m from 3Q 2022). Profit margin: 13% (up from net loss in 3Q 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings. Announcement • Jan 18
Bliss GVS Pharma Limited to Report Q3, 2023 Results on Jan 24, 2023 Bliss GVS Pharma Limited announced that they will report Q3, 2023 results on Jan 24, 2023 Announcement • Dec 31
Bliss GVS Pharma Limited Appoints Mr. Deepak Sawant as Chief Financial Officer Bliss GVS Pharma Limited appointed Mr. Deepak Sawant as Chief Financial Officer with effect from December 30, 2022. Mr. Deepak Sawant aged 43 years was appointed as Company's DGM Accounts and Finance on March 16, 2020. Mr. Sawant is a qualified Chartered Accountant and holds Bachelor of Commerce degree from Mumbai University. He has more than 20 years of post-qualification work experience having extensive expertise in Finance and Accounts, Taxation, Financial and Strategic Planning, Fund management. Prior to joining the Company, he was associated with companies like Enaltec Labs Pharma Pvt. Ltd., FDC Ltd. and Zoetis India Ltd. He has rich experience in leadership role managing finance and accounts function majorly in pharmaceutical sector. He has extensive expertise in Strategy and financial planning, Corporate Finance, Treasury, Budgeting, Taxation. He has track record of leading teams, strengthening operational and financial controls, driving operational efficiency. Mr. Sawant shall be responsible for Strategy, Accounting, Treasury, Financial Planning & Analysis and Taxation. Mr. Deepak Sawant is not related to any of the Directors or the Key Managerial Personnel or any of their relatives. Reported Earnings • Nov 08
Second quarter 2023 earnings released: EPS: ₹1.33 (vs ₹2.05 in 2Q 2022) Second quarter 2023 results: EPS: ₹1.33 (down from ₹2.05 in 2Q 2022). Revenue: ₹1.75b (down 11% from 2Q 2022). Net income: ₹138.5m (down 35% from 2Q 2022). Profit margin: 7.9% (down from 11% in 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 45 percentage points per year, which is a significant difference in performance. Announcement • Oct 30
Bliss GVS Pharma Limited to Report Q2, 2023 Results on Nov 07, 2022 Bliss GVS Pharma Limited announced that they will report Q2, 2023 results on Nov 07, 2022 Reported Earnings • Aug 04
First quarter 2023 earnings released: EPS: ₹2.48 (vs ₹2.35 in 1Q 2022) First quarter 2023 results: EPS: ₹2.48 (up from ₹2.35 in 1Q 2022). Revenue: ₹1.96b (up 16% from 1Q 2022). Net income: ₹257.2m (up 6.0% from 1Q 2022). Profit margin: 13% (down from 14% in 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Announcement • Jul 28
Bliss GVS Pharma Limited to Report Q1, 2023 Results on Aug 03, 2022 Bliss GVS Pharma Limited announced that they will report Q1, 2023 results on Aug 03, 2022 Announcement • Jun 29
Bliss GVS Pharma Limited Declares Final Dividend for the Financial Year Ended March 31, 2022 Bliss GVS Pharma Limited at its AGM held on June 28, 2022, declared final dividend of 50%, that is INR 0.50 per equity share on face value of INR 1 each for the financial year ended March 31, 2022. Upcoming Dividend • Jun 13
Upcoming dividend of ₹0.50 per share Eligible shareholders must have bought the stock before 20 June 2022. Payment date: 28 July 2022. Payout ratio is a comfortable 34% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of Indian dividend payers (1.8%). Lower than average of industry peers (1.0%). Recent Insider Transactions • Jun 10
Executive & Whole Time Director recently bought ₹21m worth of stock On the 6th of June, Vibha Sharma bought around 250k shares on-market at roughly ₹84.99 per share. In the last 3 months, they made an even bigger purchase worth ₹26m. Insiders have collectively bought ₹88m more in shares than they have sold in the last 12 months. Reported Earnings • Jun 08
Full year 2022 earnings released Full year 2022 results: Revenue: ₹7.47b (up 30% from FY 2021). Net income: ₹150.4m (down 78% from FY 2021). Profit margin: 2.0% (down from 12% in FY 2021). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings. Announcement • Jun 03
Bliss GVS Pharma Limited Announces Resignation of Mr. Vipul B. Thakkar as Chief Financial Officer Bliss GVS Pharma Limited announced that Mr. Vipul B. Thakkar has tendered his resignation from the position of Chief Financial Officer of the Company due to his personal reasons. Mr. Vipul B. Thakkar will continue to be with the Company till closing of business hours of June 30, 2022. Recent Insider Transactions • May 29
Executive & Whole Time Director recently bought ₹9.5m worth of stock On the 25th of May, Shruti Vishal Rao bought around 130k shares on-market at roughly ₹72.84 per share. In the last 3 months, there was an even bigger purchase from another insider worth ₹26m. Insiders have collectively bought ₹35m more in shares than they have sold in the last 12 months. Valuation Update With 7 Day Price Move • May 27
Investor sentiment improved over the past week After last week's 16% share price gain to ₹84.10, the stock trades at a trailing P/E ratio of 58x. Average trailing P/E is 20x in the Pharmaceuticals industry in India. Total loss to shareholders of 48% over the past three years. Announcement • Apr 24
Bliss GVS Pharma Limited to Report Q4, 2022 Results on Apr 30, 2022 Bliss GVS Pharma Limited announced that they will report Q4, 2022 results on Apr 30, 2022 Recent Insider Transactions • Apr 03
Executive & Whole Time Director recently bought ₹26m worth of stock On the 31st of March, Vibha Sharma bought around 350k shares on-market at roughly ₹73.53 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₹51m more in shares than they have sold in the last 12 months. Reported Earnings • Feb 01
Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint Third quarter 2022 results: ₹4.83 loss per share (down from ₹2.48 profit in 3Q 2021). Revenue: ₹2.16b (up 32% from 3Q 2021). Net loss: ₹501.1m (down 296% from profit in 3Q 2021). Revenue missed analyst estimates by 16%. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Dec 27
Investor sentiment improved over the past week After last week's 20% share price gain to ₹114, the stock trades at a trailing P/E ratio of 15.3x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total loss to shareholders of 30% over the past three years. Reported Earnings • Nov 03
Second quarter 2022 earnings released: EPS ₹2.05 (vs ₹1.99 in 2Q 2021) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2022 results: Revenue: ₹1.96b (up 29% from 2Q 2021). Net income: ₹212.7m (up 3.7% from 2Q 2021). Profit margin: 11% (down from 14% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 16% per year. Upcoming Dividend • Sep 06
Upcoming dividend of ₹0.50 per share Eligible shareholders must have bought the stock before 13 September 2021. Payment date: 20 October 2021. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.8%). Reported Earnings • Aug 02
First quarter 2022 earnings released: EPS ₹2.35 (vs ₹1.57 in 1Q 2021) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹1.76b (up 36% from 1Q 2021). Net income: ₹242.5m (up 50% from 1Q 2021). Profit margin: 14% (up from 13% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Reported Earnings • May 14
Full year 2021 earnings released: EPS ₹6.64 (vs ₹9.43 in FY 2020) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹5.97b (down 13% from FY 2020). Net income: ₹684.9m (down 30% from FY 2020). Profit margin: 12% (down from 14% in FY 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Announcement • May 12
Bliss GVS Pharma Limited Recommends Final Dividend for the Year Ended March 31, 2021 Bliss GVS Pharma Limited recommended final dividend of 50% i.e. 0.50 paisa per equity share on face value of INR 1 each for the financial year ended March 31, 2021, subject to approval of the shareholders in the upcoming AGM of the company. Valuation Update With 7 Day Price Move • Apr 26
Investor sentiment improved over the past week After last week's 15% share price gain to ₹107, the stock trades at a trailing P/E ratio of 15.5x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total loss to shareholders of 45% over the past three years. 
